NCT05346055 is a NA clinical trial of Engage Prism (2.0) in Depression, sponsored by Weill Medical College of Cornell University.

Who is sponsoring NCT05346055?

NCT05346055 is sponsored by Weill Medical College of Cornell University.

What drugs are being tested in NCT05346055?

Interventions in NCT05346055: Engage Prism (2.0).

What condition does NCT05346055 study?

NCT05346055 studies Depression.

Is NCT05346055 still recruiting?

NCT05346055 is currently completed. Last updated 28 June 2023.

Are results published for NCT05346055?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-06-28 · How we verify

NCT05346055

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Feasibility of Engage Therapy With Video Support for Homebound Older Adults

Completed NA Results posted Last updated 28 June 2023

What this trial tests

NA trial testing Engage Prism (2.0) in Depression in 8 participants. Completed in 30 September 2022.

Timeline

12 May 2022

Primary endpoint
30 September 2022

30 September 2022

Quick facts

Lead sponsor	Weill Medical College of Cornell University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	12 May 2022
Primary completion	30 September 2022
Estimated completion	30 September 2022
Sites	1 location across United States

Drugs / interventions tested

Engage Prism (2.0)

Conditions studied

Depression — all drugs for Depression →

Sponsor

Weill Medical College of Cornell University

Who can join

60 and older, any sex, with Depression. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Acceptability: Client Satisfaction Questionnaire (CSQ) Primary · 6 weeks (part-way through treatment)

The CSQ is a 3 - item questionnaire assessing client satisfaction with the treatment provided partway through the treatment (6 weeks). Scores range from 3 (least satisfied) to 12 (most satisfied).

Group	Value	95% CI
Engage Prism 2.0	10.5	± 4.34

Acceptability: Client Satisfaction Questionnaire (CSQ) Primary · 12 weeks (post treatment)

The CSQ is a 3 - item questionnaire assessing client satisfaction with the treatment provided assessed at 3 weeks post treatment (at 12 weeks) Scores range from 3 (least satisfied) to 12 (most satisfied).

Group	Value	95% CI
Engage Prism 2.0	9	± 0

Feasibility: Client Enrollment Primary · Baseline

Feasibility will be measured as the number of clients who are referred to the program, meet eligibility and accept the intervention (versus refuse).

Group	Value	95% CI
Engage Prism 2.0	8

Hamilton Depression Rating Scale Secondary · Baseline, 9 weeks (end of treatment)

Change in depression scores from Baseline to 9 weeks. Scores range from 0 (no depression) to 54 (very severe depression).

Group	Value	95% CI
Engage Prism 2.0	8.67	± 2.52

Hamilton Depression Rating Scale Secondary · Baseline, 12 weeks (post treatment)

Change in depression score from Baseline to 12 weeks post treatment. Scores range from 0 (no depression) to 54 (very severe depression).

Group	Value	95% CI
Engage Prism 2.0	0.5	± 0.707

Sponsor's own description

The primary aim in this pilot project is to test the feasibility, acceptability and impact (decreased depressive symptoms) of a brief behavioral treatment for depression (Engage) combined with video social support (PRISM 2.0) among socially isolated/lonely case management clients who endorse depressive symptoms. Eligible participants will be offered the combination of Engage and Prism 2.0, called Engage-Prism. The investigators hypothesize that the intervention (Engage Therapy With Video Support) will be accepted by participants, improve depressive symptom, and be feasible to complete.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Depression

Currently open trials in the same condition.

NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting

Other Weill Medical College of Cornell University trials

Trials by the same sponsor.

NCT07485712 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2 · NA · not yet recruiting
NCT05811338 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1 · NA · not yet recruiting
NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT06818734 — Implementation of a Clinical Decision Support Tool for Postpartum Depression · NA · not yet recruiting
NCT07485725 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 3 · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05346055 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Weill Medical College of Cornell University
Last refreshed: 28 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05346055.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing